Nothing to do and all day to do it in by Petsko, Gregory A
Too much work, and no vacation,
Deserves at least a small libation.
So hail! my friends, and raise your glasses,
Work’s the curse of the drinking classes.
Oscar Wilde
With me a change of trouble is as good as a vacation.
David Lloyd George
There is probably no more obnoxious class of citizen, 
taken end for end, than the returning vacationist.
Robert Benchley
Sitting on the deck of the summer house, admiring the 
way the late afternoon sun dappled the surface of the bay 
in  the  distance,  I  hadn’t  a  care  in  the  world.  (Well, 
actually, I had several, but I was doing my best to forget 
about them.) The dogs had just finished taking me for a 
long  walk,  the  heat  of  the  day  had  given  way  to  a 
comfortable breeze, I had managed to avoid doing any 
major chores around the place, a cool drink had perched 
itself on the arm of my chair - all in all, life felt pretty 
good. At such times the mind can afford the luxury of 
wandering,  and  mine  did.  Later,  when  I  realized  my 
column was due, I had the choice of dragging it back, or 
of  sharing  with  you  the  places  it  visited.  Guess  which 
option I picked?
What’s in a name?
Headline in this morning’s London Times: “Rebels breach 
Gaddafi compound”.
Headline in this morning’s Los Angeles Times: “Blasts 
rattle Tripoli as Libyan rebels encircle Kadafi compound”.
Headline in this morning’s Chicago Sun-Times: “Gadhafi 
son rallies supporters; rebels control most of Tripoli”.
Headline in this morning’s New York Times: “Qaddafi’s 
Rule Crumbling as Loyalists Fight On in Tripoli”.
Headline  in  this  morning’s  Boston  Globe,  which  is 
owned by the same news agency: “Rebels try to stamp out 
Loyalists, Khadafy at large”.
Headline in this morning’s Le Monde: “Les insurgés ont 
pénétré dans le quartier général de Kadhafi à Tripoli”.
Headline  in  this  morning’s  Neue  Zürcher  Zeitung: 
“Erste Ghadhafi-Kämpfer ergeben sich”.
Headline  in  The  Sun  this  morning:  “Winslet  flees 
inferno on Branson’s £90 million island”.
OK, what did you expect from The Sun? But look at the 
others.
During  the  Arab  Spring,  which  is  now  the  Arab 
Summer, I have seen every permutation imaginable. First 
letters have varied from G to Q to K - sometimes with a 
following H, sometimes without. The H has also made 
appearances  in  various  positions  in  the  middle  of  the 
name,  an  area  also  populated,  seemingly  randomly,  by 
one or more Ds and Fs. Not to be outdone, the last letter 
has  also  ranged  from  Y  to  I  and,  in  one  memorable 
instance,  YI.  Once  I  saw  two  completely  different 
spellings in the same newspaper. All of which raises an 
interesting question: when the rebels finally capture him, 
how do they know they have the right man: Moammar 
Quaddhafi or ‘Mu’ammar’ Kadafy?”
Random thoughts
Speaking of randomness, a recent article in Nature Reviews 
Drug Discovery (2011, 10:507-519 “How were new medi-
cines  discovered?”)  reports  that,  out  of  the  259  agents 
that were approved by the US Food and Drug Adminis-
tration between 1999 and 2008, 75 were first-in-class drugs 
with new molecular mechanisms of action (MMOAs, that 
is  to  say,  new  targets,  basically),  and  out  of  these,  50 
(67%) were small molecules and 25 (33%) were biologics. 
The results also show that the contribution of phenotypic 
screening to the discovery of first-in-class small-molecule 
drugs exceeded that of target-based approaches - with 28 
and 17 of these drugs coming from the two approaches, 
respectively. The authors state that this difference occur-
red “in an era in which the major focus was on target-
based approaches”. They go on to postulate “that a target-
centric  approach  for  first-in-class  drugs,  without  con-
sideration of an optimal MMOA, may contribute to the 
current  high  attrition  rates  and  low  productivity  in 
pharma  ceutical  research  and  development.”  Nature 
Medicine promptly published a short piece on the paper 
with the catchy title, “Random screening trumps targeted 
drug design” (2011, 17:911). © 2010 BioMed Central Ltd
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that it is not at all clear to me that, during the period in 
question, the major focus was on target-based approaches. 
It may have been so in cancer drug discovery (I call this 
the Gleevec effect), but my experience in consulting with 
a lot of biotech and pharmaceutical companies was that 
random screening was the major focus in most projects 
for most of that decade. Assuming that targeted efforts 
predominated may give too much weight to the impact of 
the human genome sequence and other genomics-based 
programs; true, they did produce ‘targets’ in abundance, 
but almost none were validated targets and an industry 
suddenly awash in targets of uncertain value was, if any-
thing,  more  likely,  I  think,  to  fall  back  on  cell-based 
screens that didn’t necessarily require a specific target. 
My point is that it is crucial to establish what the domi-
nant approaches really were if you’re going to conclude 
what  Nature  Medicine  concluded,  because  the  issue  is 
not how many new drugs came out of each approach, it’s 
how many came out of each approach relative to the total 
number of projects that used each approach. If you don’t 
have that information, you may end up making the same 
mistake you would make in concluding that white sheep 
are dumber than black sheep because more of them are 
hit by cars, without taking into account that there are a 
hell of a lot more white sheep, period.
The  second  problem  I  have  is  that  recent  data  may 
contradict  the  whole  notion  that  the  industry  suffers 
from “high attrition rates and low productivity”. This year 
is  poised  to  produce  a  bumper  crop  of  new  approved 
drugs, probably the highest number since the AIDS drug 
boom of the 1990s. Most of these new drugs were found 
by  targeted  approaches.  Many  of  the  more  thoughtful 
pharma  ceutical researchers I know have turned sour on 
random  screening  -  at  least  of  non-natural-product 
libraries - and are rediscovering targeted drug design. To 
be fair, a detailed reading of the original article would 
reveal a more balanced discussion than that suggested by 
the Nature Medicine news piece, so one moral might be, 
“Always  read  the  original  paper”.  But  a  second  moral 
would  seem  to  be  that  it  is  very  dangerous  to  draw 
conclusions about today from studies of yesterday when 
things today change as fast as they do.
The friendlier skies?
Speaking  of  change,  it  seems  change  of  sorts  may  be 
coming to air travel. One of the real problems with being 
a biologist of any kind, but especially a genome biologist, 
is  that  our  increasingly  international  field  means  you 
have to travel a lot for business, and anyone who travels a 
lot for business will almost certainly become reluctant to 
travel for pleasure. Air travel in particular is the modern 
equivalent of the ancient Chinese sport of pulling out the 
fingernails, one by one. So I was delighted this morning 
when I saw a news feed that indicated a new set of airline 
passenger  rights  had  just  gone  into  effect  in  the  US. 
(Amazing:  passengers  have  rights.  Who  knew?)  One 
change  is  that  passengers  involuntarily  bumped  from 
oversold flights are now eligible for more money. Under 
the new rule, bumped passengers can get up to $650 if 
the  airline  can  get  them  to  their  destination  within  a 
short period of time (within 1-2 hours of their originally 
scheduled  arrival  time  for  domestic  flights),  or  up  to 
$1,300 if they are delayed for a long time. Previously, the 
amounts were capped at $400 and $800, respectively.
My advice would be to always take the cash rather than 
flight vouchers, which they offer first. After all, if you take 
a flight voucher, you are accepting an opportunity for that 
airline to stick it to you again.
In the second big change, international flights finally 
get  a  tarmac  delay  limit  -  sort  of.  International  flights 
stuck on US airport tarmacs for more than 4 hours must 
now allow passengers to get off the plane or face huge 
fines, with exceptions allowed for safety, security or air-
traffic-control-related reasons. That sounds like a good 
thing until you realize two other things: (1) the limit used 
to be 12 hours! I wouldn’t even want to do something fun 
for  12  hours.  (2)  The  limit  is  still  4  hours.  4  hours  of 
unmitigated hell.
Finally, if you pay extra to check in a piece of luggage 
and the airline loses your bag, it must now refund the bag 
fee.  That’s  right,  until  now,  they  could  both  lose  your 
luggage and charge you for the privilege.
So I suppose all this is an improvement of some sort, in 
that we have gone from having the rights of galley slaves to 
having the rights of - well, a higher class of galley slaves. 
But the moral, I think, is that if God had intended Man to 
fly, He would have never have given us the airlines.
Too good to pass up
Speaking of morals, another important one is never to 
give a wise-guy a golden opportunity. I was idly looking 
over  my  emails  (I  feel  no  compulsion  to  answer  them 
while on vacation, but I’ve never been able to stop looking 
at  them)  when  I  saw  a  message  from  one  of  my  best 
friends, also a scientist. He wanted me to read over an 
author’s lay summary of a paper he was submitting (the 
journal  has  a  requirement  for  such  author  summaries, 
and they must be approved by someone not an author of 
the paper). Probably because of this column, I often get 
asked to do that sort of thing, and this one was no trouble - 
the science was excellent, and he writes beautifully - but 
the email was what caught my attention. What he meant to 
ask me was for a statement that the author summary was 
OK;  what  he  wrote  was:  “At  this  point  an  email 
commenting that the author is OK is all I need.”
Well,  that  was  like  giving  Moammar  (Muhamar? 
Mu’ammar?)  Qadhafi  (Khadafi?  Gadaffy?)  access  to 
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an email to the editor of the journal, who knows us both, 
with a cc to my friend. I quoted his exact message at the 
top and then wrote, “I regret to say that, on the basis of 
thirty years of friendship, I cannot in good conscience 
attest that the author is OK.”
I hit ‘Send’, closed the lid on my MacBook Air, and sank 
back in my deck chair. The sun had almost set, and the 
sky was a Turner canvas of purple and red. I heaved a 
deep sigh of contentment. The perfect end to a perfect 
vacation day.
Note
Variants  in  spelling  can  arise  from  different  trans-
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